Takanori Yasu
Takanori Yasu
Association between Serum Levels of Interleukin-6 and Stroke, Cardiovascular Events, and Alzheimer's Disease Dementia [0.03%]
血清IL-6水平与脑卒中、心血管病事件及阿尔茨海默型痴呆的关系
Kazuo Kitagawa,Sono Toi,Hiroshi Yoshizawa et al.
Kazuo Kitagawa et al.
Aims: The blood inflammatory marker interleukin 6 (IL-6) has been shown to predict future stroke, major adverse cardiovascular events (MACEs), and dementia. However, no study has yet examined this relationship in the same...
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis [0.03%]
血管生成素样蛋白3在脂质异常和动脉粥样硬化治疗中的新突破
Hirotaka Fukami,Yuichi Oike
Hirotaka Fukami
Dyslipidemia is a major risk factor for atherosclerosis and subsequent cardiovascular disease (CVD). Despite conventional treatment with statins, ezetimibe, or PCSK9 inhibitors, there are cases of familial hypercholesterolemia (FH) in which...
Screening for Familial Hypercholesterolemia in Children and its Cost-Effectiveness [0.03%]
儿童家族性高胆固醇血症的筛查及其费用效益分析
Keiko Nagahara
Keiko Nagahara
Assessments of Atherosclerosis and Treatment Strategies for Heterozygous Familial Hypercholesterolemia [0.03%]
异染性家族高胆固醇血症的动脉粥样硬化评估及治疗策略
Hayato Tada,Mariko Harada-Shiba
Hayato Tada
Patients with familial hypercholesterolemia (FH) carry an extremely elevated cardiovascular risk because of lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C). The Japan Atherosclerosis Society (JAS) complies with the...
Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia [0.03%]
胆固醇酯转移蛋白缺乏和高α脂蛋白血症
Akihiro Inazu
Akihiro Inazu
Cholesteryl ester transfer protein (CETP) deficiency and lipoprotein phenotypes with CETP inhibitors were compared. The effects on atherosclerotic cardiovascular disease (ASCVD) and the recently suggested retinal disease of age-related macu...
Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial [0.03%]
Pemafibrate对胆固醇合成和吸收的影响：一项II期临床试验的事后亚组分析
Shizuya Yamashita,Eiichi Araki,Hidenori Arai et al.
Shizuya Yamashita et al.
Aim: Recently, we reported that a pemafibrate extended-release (XR) formulation lowered low-density lipoprotein cholesterol (LDL-C) and cholesterol synthesis and absorption markers in a phase 2 clinical pharmacology study...
Association of Social Participation with Cardiovascular Risk Factors: A Systematic Review [0.03%]
社会参与与心血管危险因素关系的系统评价
Moemi Miura,Ai Ikeda,Shiho Sato et al.
Moemi Miura et al.
Aim: Although social participation, defined as involvement in social activities, may be beneficial for cardiovascular health, evidence about the association remains limited. This systematic review summarized the relations...
Serum Total Cholesterol and Fatal Subarachnoid Hemorrhage in 120,000 Japanese: A Pooled Analysis of Data from 12 Cohorts [0.03%]
日本12万人队列的汇总分析：血脂与蛛网膜下腔出血死亡率的关系
Atsushi Satoh,Hisatomi Arima,Sachiko Tanaka-Mizuno et al.
Atsushi Satoh et al.
Aim: The aim of this study was to clarify the association between serum total cholesterol and fatal subarachnoid hemorrhage in Japanese men and women. Met...
Impact of a Physician-led Strike Early-Strike Strong Lipid-Lowering Protocol Incorporating PCSK9 Inhibitors for Patients with Acute Myocardial Infarction [0.03%]
急性心肌梗死患者早期强化降脂方案中应用PCSK9抑制剂的效果：一项医师主导的倡议研究
Riku Arai,Yuta Hotsubo,Yuki Nakajima et al.
Riku Arai et al.
Aims: Intensive lipid-lowering therapy is recommended for secondary prevention of cardiovascular events after acute myocardial infarction (AMI). However, the prescription rate of PCSK9 inhibitors (PCSK9is) remains low amo...